Last Updated: 16 Sep 2024
Executive Summary
ATRION Corporation (ATRI) is a medical device company that operates in the fluid management, cardiovascular, and ophthalmic sectors. The company's stock is currently trading at $459.92, with a market capitalization of $809.4 million. ATRION has a strong financial position, with positive EBITDA, EPS, and revenue growth. The company's stock is currently undervalued based on its fundamentals and technical indicators.
Company Overview
ATRION Corporation is headquartered in Allen, Texas and has operations in the United States, Germany, and internationally. The company develops, manufactures, and sells products for fluid management, cardiovascular, and ophthalmic applications. ATRION's products are used in a variety of medical settings, including hospitals, clinics, and ambulatory surgery centers.
Fundamental Analysis
ATRION's financial performance has been strong in recent years. The company's revenue has grown by an average of 10% per year over the past five years. In 2023, ATRION reported revenue of $181.6 million, up from $164.7 million in 2022. The company's net income has also grown in recent years, from $24.9 million in 2022 to $32.5 million in 2023.
ATRION's financial ratios are also healthy. The company has a strong balance sheet, with total assets of $245.2 million and total liabilities of $109.7 million. The company's debt-to-equity ratio is 0.45, which is below the industry average. ATRION also has a strong cash flow position, with operating cash flow of $42.3 million in 2023.
Technical Analysis
ATRION's stock price has been in a downtrend since reaching a high of $500.80 in August 2023. The stock price has fallen by over 20% since then. The stock's technical indicators are currently bearish, with the RSI below 50 and the MACD below the signal line.
Short Term Outlook
The short-term outlook for ATRION's stock is bearish. The stock price is in a downtrend and the technical indicators are bearish. The stock is likely to continue to decline in the short term.
Long Term Outlook
The long-term outlook for ATRION's stock is bullish. The company has a strong financial position and a growing revenue stream. The company's products are used in a variety of medical settings and the demand for these products is expected to grow in the future. The stock is currently undervalued based on its fundamentals and technical indicators. The stock is likely to appreciate in the long term.
Analyst Recommendations
The majority of analysts who cover ATRION have a "hold" rating on the stock. However, there are a few analysts who have a "buy" rating on the stock. The average analyst target price for ATRION is $300.
